Dr. Geisler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 314-362-1408Fax+1 314-362-3752
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Neuromuscular Medicine (Neurology), 2013 - 2014- Washington University/B-JH/SLCH ConsortiumResidency, Neurology, 2009 - 2013
Charité - Universitätsmedizin BerlinClass of 2001
Certifications & Licensure
MO State Medical License 2013 - 2025- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Publications & Presentations
PubMed
- 19 citationsVincristine- and bortezomib-induced neuropathies - from bedside to bench and back.Stefanie Geisler
Experimental Neurology. 2021-02-01 - 96 citationsGene therapy targeting SARM1 blocks pathological axon degeneration in mice.Stefanie Geisler, Shay X. Huang, Amy Strickland, Ryan A. Doan, Daniel W. Summers
The Journal of Experimental Medicine. 2019-02-04 - 97 citationsVincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration programStefanie Geisler, Ryan A. Doan, Galen Cheng, Aysel Cetinkaya-Fisgin, Shay X. Huang
JCI Insight. 2019-09-05
Press Mentions
List of Temporary Practice Permits Granted May 5, 2020May 5th, 2020
Gene Therapy Blocks Peripheral Nerve Damage in MiceJanuary 16th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
